Emerging Markets Earnings Roundup: Johnson & Johnson (Part 1)
This article was originally published in PharmAsia News
Second quarter earnings from Johnson & Johnson shed light on the view on biosimilar launches of Remicade and how the company hopes to streamline its varied arms abroad.
You may also be interested in...
Products launched since 2009 have yielded the highest pharmaceutical sales growth among the 10 biggest biopharma companies, more than offsetting a substantial patent cliff. Zytiga and Olysio already have passed the $1 billion sales threshold this year, with Xarelto on pace to do so.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.